(XENE) - Earnings & Price History

XENE: - 3.1, $56.69M, 0.00 (0.00%)

Sector: Healthcare - Industry: Biotechnology

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It offers Glybera, a gene therapy product for the treatment of patients with orphan lipid disorder lipoprotein lipase deficiency. The company is also developing TV-45070, which is in Phase IIb clinical trials in patients with post-herpetic neuralgia; GDC-0276 and GDC-0310 that are in Phase I clinical trials for the treatment of pain; and XEN801, a stearoyl Co-A desaturase-1 inhibitor that is in Phase II clinical trials in patients with moderate to severe facial acne. Its pre

Past XENE reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-03-08AMC-0.428.48.358.17.878.45-2.99%3.70%0.60%111.83K
2017-03-06AMC-0.428.48.28.28.198.552.44%2.44%109.15K
2016-11-03AMC-0.437.657.77.77.558.05-0.65%-0.65%22.26K
2016-08-03AMC-0.487.417.367.497.417.491.77%-1.07%0.68%2.26K
2016-05-10AMC-0.216.7356.676.676.686.830.97%0.97%8.33K
2016-03-08AMC-0.167.277.337.67.257.63.68%-4.34%-0.82%6.15K
2015-11-10AMC-0.027.888.158.887.868.888.96%▲-11.26%-3.31%29.72K
2015-08-10AMC-0.169.169.629.549.169.98-0.83%-3.98%-4.78%21.70K
2015-05-12AMC0.1413.6914.6613.2514.86-6.62%111.85K
2015-03-12AMC18.3518.1618.8517.9218.873.80%-2.65%1.05%24.75K

Login | Register
Friday Nov 16, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades